MedTrace Logo

Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease

NCT02002585 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-12-06

No results posted yet for this study

Summary

Kidney protection study (KPS 1) is a prospective randomized clinical study comparing the use of renal denervation (RDN) and optimal medical therapy in subjects with chronic kidney disease stage 3-4 and resistant arterial hypertension to optimal medical therapy alone. Renal denervation is a modern endovascular method used to treat resistant hypertension. The method is being extended to other groups of patients, where the sympathetic tone is increased beyond resistant hypertension. Because of the character of the disease, we hypothesize that renal denervation can reduce or prevent progressive deterioration of kidney functions in this patient population. The aim of this clinical study is to show that renal denervation has protective effects on the progression of chronic renal insufficiency.

Conditions

  • Arterial Hypertension
  • Chronic Renal Insufficiency

Interventions

PROCEDURE

Renal denervation

Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.

Sponsors & Collaborators

  • General University Hospital, Prague

    collaborator OTHER

  • Na Homolce Hospital

    collaborator OTHER

  • Mount Sinai Hospital, New York

    collaborator OTHER

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Jean Claude Lubanda, Ass.Prof. MD · Charles University, Czech Republic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02002585 on ClinicalTrials.gov